PPIB and atrial fibrillation: Although CysC has multi-targeted neuroprotection in the brain, its levels expression in patients with AD, DLB and AF-GP might not be sufficient to maintain the long-term inhibition of Αβ deposition and adequately protect the neuronal cells from Aβ toxicity and oxidative stress.